SOLUBILITY AND DISSOLUTION CONSIDERATIONS FOR AMORPHOUS SOLID DISPERSIONS - Pharmaceutical Amorphous Solid Dispersions - page 252

31. Amidon, G.L., Lennernas, H., Shah, V.P., and Crison, J.R. (1995) Theoretical basis for a
biopharmaceutical drug classification: correlation of in vitro drug product dissolution and
in vivo bioavailability. Pharm. Res. , 12:413-420.
32. Martinez, M.N. and Amidon, G.L. (2002) A mechanistic approach to understanding the
factors affecting drug absorption: a review of fundamentals. Clin. Pharmacol. , 42(6):
620-643.
33. U.S. Department of Health and Human Services (2000) Guidance for Industry: Waiver of In
Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage
Forms Based on a Biopharmaceutics Classification System , Center for Drug Evaluation and
Research (CDER), Food and Drug Administration, Rockville, MD.
34. U.S. Department of Health and Human Services (2000) Guidance for Industry: Waiver on
In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral
Dosage Forms Based on a Biopharmaceutics Classification Systems , Center for Drug
Evaluation and Research (CDER), Food and Drug Administration, Rockville, MD.
35. Li, S., He, H., Lakshman, P.J., Hequn, Y., and Serajuddin, A.Y.M. (2005) IV-IVC
considerations in the development of immediate-release oral dosage form. J. Pharm. Sci. ,
94(7):1396-1416.
36. Lu, Y., Kim, S., and Park, K. (2011) In vitro - in vivo correlation: perspectives on model
development. Int. J. Pharm. , 418(1):142-148.
37. Brouwers, J., Brewster, M.E., and Augustijns, P. (2009) Supersaturating drug delivery
systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. , 98(8):
2549-2572.
38. Gao, P. and Shi, Y. (2012) Characterization of supersaturatable formulations for improved
absorption of poorly soluble drugs. AAPS J. , 14(4):703-713.
39. Kawakami, K. (2012) Modification of physicochemical characteristics of active pharmaceu-
tical ingredients and application of supersaturatable dosage forms for improving bio-
availability of poorly absorbed drugs. Adv. Drug Deliv. Rev. , 64(6):480-495.
40. Singh, A., Worku, Z.A., and Van DenMooter, G. (2011) Oral formulation strategies to improve
solubility of poorly water-soluble drugs. Expert Opin. Drug Deliv. , 8(10):1361-1368.
41. Hancock, B.C. (2002) Disordered drug delivery: destiny, dynamics and the Deborah number.
J. Pharm. Pharmacol. , 54(6):737 746.

42. Mosharraf, M. and Nyström, C. (1999) The effect of dry mixing on the apparent solubility of
hydrophobic, sparingly soluble drugs. Eur. J. Pharm. Sci. , 9(2):145-156.
43. Bollag, G., Hirth, P., Tsai, J., et al. (2010) Clinical efficacy of a RAF inhibitor needs broad
target blockade in BRAF-mutant melanoma. Nature , 467(7315):596-599.
44. Goldberg, A.H., Gibaldi, M., and Kanig, J.L. (1966) Increasing dissolution rates and
gastrointestinal absorption of drugs via solid solutions and eutectic mixtures III: experimental
evaluation of griseofulvin-succinic acid solid solution. J. Pharm. Sci. , 55(5):487-492.
45. Hancock, B.C. and Parks, M. (2000) What is the true solubility advantage for amorphous
pharmaceuticals? Pharm. Res. , 17(4):397-404.
46. Joshi, H.N., Tejwani, R.W., Davidovich, M., et al. (2004) Bioavailability enhancement of a
poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80
mixture. Int. J. Pharm. , 269(1):251-258.
47. Kennedy, M., Hu, J., Gao, P., et al. (2008) Enhanced bioavailability of a poorly soluble VR1
antagonist using an amorphous solid dispersion approach: a case study. Mol. Pharm. ,
5(6):981-993.

-